ID   Mel IL/R
AC   CVCL_B6KF
DR   cancercelllines; CVCL_B6KF
DR   Wikidata; Q112129274
RX   PubMed=30551515;
CC   Selected for resistance to: ChEBI; CHEBI_63637; Vemurafenib (Zelboraf; PLX4032).
CC   Sequence variation: Mutation; HGNC; HGNC:1097; BRAF; Simple; p.Val600Lys (c.1798_1799delGTinsAA); ClinVar=VCV000375941; Zygosity=Unspecified (PubMed=30551515).
CC   Derived from site: Metastatic; Chest, hypodermis; UBERON=UBERON_0001443+UBERON_0002072.
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_B6KD ! Mel Il
CA   Cancer cell line
DT   Created: 17-03-22; Last updated: 19-12-24; Version: 6
//
RX   PubMed=30551515; DOI=10.1016/j.biopha.2018.11.109;
RA   Ryabaya O., Prokofieva A., Akasov R., Khochenkov D., Emelyanova M.,
RA   Burov S., Markvicheva E., Inshakov A.N., Stepanova E.V.;
RT   "Metformin increases antitumor activity of MEK inhibitor binimetinib
RT   in 2D and 3D models of human metastatic melanoma cells.";
RL   Biomed. Pharmacother. 109:2548-2560(2019).
//